Ensysce Biosciences, Inc.ENSCNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank75
5Y CAGR-20.1%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-20.1%/yr
Long-term compound
Percentile
P75
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 6.74% |
| Q2 2025 | -14.51% |
| Q1 2025 | 30.12% |
| Q4 2024 | -0.51% |
| Q3 2024 | -8.99% |
| Q2 2024 | -13.14% |
| Q1 2024 | -4.73% |
| Q4 2023 | 17.12% |
| Q3 2023 | 7.63% |
| Q2 2023 | -26.64% |
| Q1 2023 | 30.41% |
| Q4 2022 | -29.31% |
| Q3 2022 | -13.55% |
| Q2 2022 | -13.89% |
| Q1 2022 | 55.81% |
| Q4 2021 | -91.12% |
| Q3 2021 | 4056.48% |
| Q2 2021 | -19.69% |
| Q1 2021 | 91.26% |
| Q4 2020 | -24.45% |
| Q3 2020 | 20.64% |
| Q2 2020 | 1.32% |
| Q1 2020 | -85.61% |
| Q4 2019 | 0.00% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |
| Q3 2018 | 0.00% |
| Q2 2018 | 0.00% |
| Q1 2018 | -100.00% |
| Q4 2017 | 0.00% |
| Q3 2017 | 0.00% |